Revised forecast
Fiscal year ending March 2027 · Full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
Sales of key strategic products, led by PADCEV, IZERVAY and VYLOY, are expected to increase substantially and absorb the decline in XTANDI sales. Selling, general and administrative expenses are expected to decrease as cost optimization through SMT continues, while research and development expenses are expected to increase due to higher clinical development costs, including those for new Phase III trials. Foreign exchange effects from the yen weakening against the euro are also expected.
Recognized an impairment loss of ¥12.0 billion on intangible assets related to certain Xyphos programs and an impairment loss of ¥16.4 billion on intangible assets associated with the strategic discontinuation of AT132. For the next fiscal year, approximately ¥80 billion has been factored in as other expenses, including the risk of impairment losses and costs associated with organizational restructuring.
| Item | Details |
|---|---|
| Net Sales | Not disclosed → ¥2,220,000 million（+3.8%） |
| Operating profit | Not disclosed → ¥395,000 million（+3.2%） |
| Profit attributable to owners of the parent | Not disclosed → ¥300,000 million（+2.9%） |
| Net income per share | Not disclosed → 167.46 yen and sen（+2.9%） |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Previous-period results | Revenue: ¥2,139,245 million; operating profit: ¥382,633 million; profit before tax: ¥376,587 million; profit for the year: ¥291,575 million; profit for the year attributable to owners of the parent: ¥291,535 million |
| Reason for the revision | Sales of key strategic products, led by PADCEV, IZERVAY and VYLOY, are expected to increase substantially and absorb the decline in XTANDI sales. Selling, general and administrative expenses are expected to decrease as cost optimization through SMT continues, while research and development expenses are expected to increase due to higher clinical development costs, including those for new Phase III trials. Foreign exchange effects from the yen weakening against the euro are also expected. |
| Details and amount of extraordinary loss | Recognized an impairment loss of ¥12.0 billion on intangible assets related to certain Xyphos programs and an impairment loss of ¥16.4 billion on intangible assets associated with the strategic discontinuation of AT132. For the next fiscal year, approximately ¥80 billion has been factored in as other expenses, including the risk of impairment losses and costs associated with organizational restructuring. |
| Dividend forecast revision | Annual dividends for the fiscal year ending March 2027 are forecast at ¥80, comprising an interim dividend of ¥40 and a year-end dividend of ¥40. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue is expected to increase in the next fiscal year, as higher sales of key strategic products, led by PADCEV, IZERVAY and VYLOY, are expected to absorb the decline in XTANDI sales. Selling, general and administrative expenses are expected to decrease as cost optimization through SMT continues, while research and development expenses are expected to increase due to higher clinical development costs, including those for new Phase III trials. Foreign exchange effects based on the assumption that the yen will weaken against the euro are also expected.